PLUR Insider Trading

Insider Ownership Percentage: 5.40%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $1,940.00

Pluri Insider Trading History Chart

This chart shows the insider buying and selling history at Pluri by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Pluri Share Price & Price History

Current Price: $1.14
Price Change: Price Increase of +0.03 (2.71%)
As of 02/2/2023 01:00 AM ET

This chart shows the closing price history over time for PLUR up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Pluri Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/20/2022Zami AbermanDirectorSell2,000$0.97$1,940.001,491,973View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Pluri (NASDAQ:PLUR)

2.81% of Pluri stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at PLUR by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Pluri Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
12/2/2022Values First Advisors Inc.48,330$38K0.0%N/A0.148%Search for SEC Filing on Google Icon
11/16/2022Jane Street Group LLC35,986$28K0.0%N/A0.110%Search for SEC Filing on Google Icon
11/14/2022Renaissance Technologies LLC104,400$81K0.0%N/A0.320%Search for SEC Filing on Google Icon
10/14/2022Green Alpha Advisors LLC56,226$44K0.0%N/A0.172%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Pluri logo
Pluri, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The firm focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.
Read More on Pluri

Today's Range

Now: $1.14
Low: $1.08
High: $1.18

50 Day Range

MA: $1.02
Low: $0.79
High: $1.30

52 Week Range

Now: $1.14
Low: $0.65
High: $2.21

Volume

85,014 shs

Average Volume

55,928 shs

Market Capitalization

$37.08 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.59

Who are the company insiders with the largest holdings of Pluri?

Pluri's top insider investors include:
  1. Zami Aberman (Director)
Learn More about top insider investors at Pluri.

Who are the major institutional investors of Pluri?

Pluri's top institutional investors include:
  1. Simplex Trading LLC — 0.00%
  2. Concourse Financial Group Securities Inc. — 0.00%
Learn More about top institutional investors of Pluri stock.

Which institutional investors are selling Pluri stock?

During the previous quarter, PLUR stock was sold by these institutional investors:
  1. Simplex Trading LLC